



<u>Procedure</u>	<u>Result</u>	<u>Units</u>	<u>Ref Interval</u>	<u>Accession</u>	<u>Collected</u>	<u>Received</u>	<u>Reported/Verified</u>
HLA Class I-Locus A*, Allele 1	SEE NOTE @			20-084-900238	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I-Locus A*, Allele 2	SEE NOTE @			20-084-900238	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I-Locus B*, Allele 1	SEE NOTE @			20-084-900238	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I-Locus B*, Allele 2	SEE NOTE @			20-084-900238	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I-Locus Bw*, Allele 1	SEE NOTE @			20-084-900238	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I-Locus Bw*, Allele 2	SEE NOTE @			20-084-900238	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I-Locus C*, Allele 1	SEE NOTE @			20-084-900238	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I-Locus C*, Allele 2	SEE NOTE @			20-084-900238	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I Panel, Interpretation	See Note @			20-084-900238	24-Mar-20	24-Mar-20	24-Mar-20
EER HLA Class I Panel, Interpretation	See Note @			20-084-900238	24-Mar-20	24-Mar-20	24-Mar-20

24-Mar-20 15:15:00 HLA Class I-Locus C*, Allele 1,HLA Class I-Locus A*, Allele 1,HLA Class I-Locus Bw*, Allele 2,HLA Class I-Locus A*, Allele 2,HLA Class I-Locus C*, Allele 2,HLA Class I-Locus B*, Allele 1,HLA Class I Panel, Interpretation,HLA Class I-Locus Bw*, Allele 1,EER HLA Class I Panel, Interpretation,HLA Class I-Locus B*, Allele 2:

Performed at: UUHC: Histocompatibility and Immunogenetics, 417 Wakara Way, Ste. 3220, SLC, UT 84108

24-Mar-20 15:15:00 HLA Class I Panel, Interpretation:
 INTERPRETIVE INFORMATION: HLA Class I Panel (ABC) NGS

Purpose: To identify HLA-A, -B, and -C allelic polymorphisms on specimens for transplant candidates and their donors.

Methodology: PCR followed by next generation sequencing of HLA-A, -B and -C loci.

Analytical Sensitivity & Specificity: >99 percent.

Limitations: Rare diagnostic errors can occur due to primer site mutations.

Test Results: Results are reported as HLA locus (A, B, or C)* followed by the two-field (four digit) assigned allele.

Disclaimer Information:

HLA typing has been performed by one or more of the following methodologies: next generation sequencing (NGS) and/or sequence specific probe hybridization (SSOP). The NMDP code provides possible rare alleles that cannot be ruled out. Additional unknown DNA polymorphisms could exist outside of the regions analyzed, the significance of which is not known.

This test was developed and its performance characteristics determined by the Histocompatibility& Immunogenetics laboratory at the University of Utah Health. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. Histocompatibility& Immunogenetics laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.

Performed at: Histocompatibility& Immunogenetics laboratory, University of Utah Health, 417 Wakara way, Suite 3220, Salt Lake City, UT 84108.

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab